These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1613744)

  • 1. Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.
    Lipinski CA; Aldinger CE; Beyer TA; Bordner J; Burdi DF; Bussolotti DL; Inskeep PB; Siegel TW
    J Med Chem; 1992 Jun; 35(12):2169-77. PubMed ID: 1613744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spiro hydantoin aldose reductase inhibitors derived from 8-aza-4-chromanones.
    Sarges R; Goldstein SW; Welch WM; Swindell AC; Siegel TW; Beyer TA
    J Med Chem; 1990 Jul; 33(7):1859-65. PubMed ID: 2113948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spiro hydantoin aldose reductase inhibitors.
    Sarges R; Schnur RC; Belletire JL; Peterson MJ
    J Med Chem; 1988 Jan; 31(1):230-43. PubMed ID: 3121857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotationally restricted mimics of rigid molecules: nonspirocyclic hydantoin aldose reductase inhibitors.
    Rizzi JP; Schnur RC; Hutson NJ; Kraus KG; Kelbaugh PR
    J Med Chem; 1989 Jun; 32(6):1208-13. PubMed ID: 2498517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorbinil: a member of the novel class of spirohydantoin aldose reductase inhibitors.
    Sarges R; Peterson MJ
    Metabolism; 1986 Apr; 35(4 Suppl 1):101-4. PubMed ID: 3083199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones as aldose reductase inhibitors.
    Yamagishi M; Yamada Y; Ozaki K; Asao M; Shimizu R; Suzuki M; Matsumoto M; Matsuoka Y; Matsumoto K
    J Med Chem; 1992 May; 35(11):2085-94. PubMed ID: 1597858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
    Negoro T; Murata M; Ueda S; Fujitani B; Ono Y; Kuromiya A; Komiya M; Suzuki K; Matsumoto J
    J Med Chem; 1998 Oct; 41(21):4118-29. PubMed ID: 9767647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.
    Kato K; Nakayama K; Mizota M; Miwa I; Okuda J
    Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1540-5. PubMed ID: 1934175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased nerve polyol levels in experimental diabetes and their reversal by Sorbinil.
    Whiting PH; Ross IS
    Br J Exp Pathol; 1988 Oct; 69(5):697-702. PubMed ID: 3143396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of potent aldose reductase inhibitors having a hydantoin structure.
    Miwa I; Hirano M; Inagaki K; Belbeoc'h C; Okuda J
    Biochem Pharmacol; 1987 Sep; 36(17):2789-94. PubMed ID: 3115267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
    Malamas MS; Hohman TC; Millen J
    J Med Chem; 1994 Jun; 37(13):2043-58. PubMed ID: 8027986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an aldose reductase inhibitor on lens metabolism, ATPases and antioxidative defense in streptozotocin-diabetic rats: an intervention study.
    Obrosova IG; Fathallah L
    Diabetologia; 2000 Aug; 43(8):1048-55. PubMed ID: 10990083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and aldose reductase inhibitory activity of 2-substituted-6-fluoro-2,3-dihydrospiro [4H-1-benzopyran-4, 4'-imidazolidine]-2',5'-diones.
    Yamaguchi T; Miura K; Usui T; Unno R; Matsumoto Y; Fukushima M; Mizuno K; Kondo Y; Baba Y; Kurono M
    Arzneimittelforschung; 1994 Mar; 44(3):344-8. PubMed ID: 8192700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
    Tomlinson DR; Moriarty RJ; Mayer JH
    Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spirohydantoin inhibitors of aldose reductase inhibit iron- and copper-catalysed ascorbate oxidation in vitro.
    Jiang ZY; Zhou QL; Eaton JW; Koppenol WH; Hunt JV; Wolff SP
    Biochem Pharmacol; 1991 Aug; 42(6):1273-8. PubMed ID: 1909528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors.
    Tilton RG; Chang K; Pugliese G; Eades DM; Province MA; Sherman WR; Kilo C; Williamson JR
    Diabetes; 1989 Oct; 38(10):1258-70. PubMed ID: 2507378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.
    Bruno G; Costantino L; Curinga C; Maccari R; Monforte F; Nicoló F; Ottanà R; Vigorita MG
    Bioorg Med Chem; 2002 Apr; 10(4):1077-84. PubMed ID: 11836118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
    Wrobel J; Dietrich A; Woolson SA; Millen J; McCaleb M; Harrison MC; Hohman TC; Sredy J; Sullivan D
    J Med Chem; 1992 Nov; 35(24):4613-27. PubMed ID: 1469692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and efficacy of structurally related spirohydantoin and spirosuccinimide aldose reductase inhibitors.
    Park YH; Barker R; Griffin B; Barratt D; DuPriest M; Brazzell K; York B; Mayer P
    Xenobiotica; 1992 May; 22(5):543-50. PubMed ID: 1413869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes].
    Kuchmerovskaia TM; Donchenko GV; Klimenko AP; Chichkovskaia GV; Pakirbaeva LV; Kozitskiĭ ZIa; Efimov AS
    Ukr Biokhim Zh (1978); 1997; 69(3):77-82. PubMed ID: 9505366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.